TABLE 6.

Indications Reporting Odds Ratio (ROR) for commonly reported adverse events with Semaglutide

	PT	a	ROR	ROR (95%Cl)
	MEDULLARY THYROID CANCER	11	123.97	123.97 (67.69–227.05)
	ALLODYNIA	11	44	44 (24.24–79.87)
	ERUCTATION	200	37.82	37.82 (32.87–43.52)
	PANCREATIC INJURY	3	35.02	35.02 (11.21–109.41)
	OBSTRUCTIVE PANCREATITIS	4	25.04	25.04 (9.35–67.03)
	DIABETIC RETINOPATHY	26	23.48	23.48 (15.96–34.56)
	THYROID MASS	23	20.15	20.15 (13.36–30.37)
DIABETES MELLITUS	RETINOPATHY	23	18.39	18.39 (12.2–27.72)
	GLYCOSYLATED HAEMOGLOBIN DECREASED	8	16.57	16.57 (8.27–33.22)
	VOMITING PROJECTILE	13	15.58	15.58 (9.03–26.88)
	HICCUPS	37	14.38	14.38 (10.41–19.87)
	IMPAIRED GASTRIC EMPTYING	34	13.56	13.56 (9.68–18.99)
	PANCREATITIS NECROTISING	10	13.13	13.13 (7.05–24.45)
	GLYCOSYLATED HAEMOGLOBIN ABNORMAL	4	12.8	12.8 (4.79–34.18)
	GLYCOSYLATED HAEMOGLOBIN INCREASED	101	12.79	12.79 (10.52–15.56)
	STARVATION KETOACIDOSIS	4	323.69	323.69 (118.06–887.5)
	ALLODYNIA	24	208.42	208.42 (138.58–313.44)
	MEDULLARY THYROID CANCER	3	69.36	69.36 (22.21–216.62)
	OBSTRUCTIVE PANCREATITIS	4	53.17	53.17 (19.86–142.36)
	FOOD AVERSION	10	45.17	45.17 (24.23–84.19)
	FOOD CRAVING	20	34.33	34.33 (22.11–53.31)
	MYOGLOBINURIA	3	33.76	33.76 (10.85–105.05)
OBESITY	BINGE EATING	5	33.52	33.52 (13.91–80.76)
	ERUCTATION	68	26.97	26.97 (21.23–34.25)
	VOMITING PROJECTILE	10	25.42	25.42 (13.65–47.33)
	BILIARY COLIC	13	24.74	24.74 (14.34–42.68)
	SENSITIVE SKIN	19	20.95	20.95 (13.35–32.89)
	PAPILLARY THYROID CANCER	5	19.54	19.54 (8.12–47.04)
	IMPAIRED GASTRIC EMPTYING	22	18.6	18.6 (12.23–28.28)
	SKIN SENSITISATION	3	18.22	18.22 (5.86–56.61)

Note: a, number of cases with available; PT, preferred term.